key: cord-0749939-53o0hpsb
authors: Sourimant, Julien; Lieber, Carolin M; Aggarwal, Megha; Cox, Robert M; Wolf, Josef D; Yoon, Jeong-Joong; Toots, Mart; Ye, Chengin; Sticher, Zachary; Kolykhalov, Alexander A; Martinez-Sobrido, Luis; Bluemling, Gregory R; Natchus, Michael G; Painter, George R; Plemper, Richard K
title: 4’-Fluorouridine is a broad-spectrum orally efficacious antiviral blocking respiratory syncytial virus and SARS-CoV-2 replication
date: 2021-05-20
journal: bioRxiv
DOI: 10.1101/2021.05.19.444875
sha: 25b61500a075b29f505961c20f5e02ec5faa76c1
doc_id: 749939
cord_uid: 53o0hpsb

The COVID-19 pandemic has underscored the critical need for broad-spectrum therapeutics against respiratory viruses. Respiratory syncytial virus (RSV) is a major threat to pediatric patients and the elderly. We describe 4’-fluorouridine (4’-FlU, EIDD-2749), a ribonucleoside analog that inhibits RSV, related RNA viruses, and SARS-CoV-2 with high selectivity index in cells and well-differentiated human airway epithelia. Polymerase inhibition in in vitro RdRP assays established for RSV and SARS-CoV-2 revealed transcriptional pauses at positions i or i+3/4 post-incorporation. Once-daily oral treatment was highly efficacious at 5 mg/kg in RSV-infected mice or 20 mg/kg in ferrets infected with SARS-CoV-2 WA1/2020 or variant-of-concern (VoC) isolate CA/2020, initiated 24 or 12 hours after infection, respectively. These properties define 4’-FlU as a broad-spectrum candidate for the treatment of RSV, SARS-CoV-2 and related RNA virus infections. One-Sentence Summary 4’-Fluorouridine is an orally available ribonucleoside analog that efficiently treats RSV and SARS-CoV-2 infections in vivo.

ferrets (2) , and using the ferret model were subsequently first to show that antiviral efficacy of molnupiravir extends to SARS-CoV-2 in vivo (3). Initial human data for molnupiravir were encouraging (4) and the drug is in advanced clinical trials for treatment of COVID-19. However, even this highly accelerated development timeline reiterates that, to have a substantial impact on a mounting pandemic, an antiviral must be approved for human use before a new pathogen 5 emerges.

We have identified RSV disease as a viable primary indication to develop a broad-spectrum antiviral drug, based on the unmet major health threat imposed by RSV and well-established protocols for clinical trials of novel anti-RSV therapeutics. RSV infections cause over 58,000 hospitalizations of children below five years of age in the United States annually, and 10 approximately 177,000 hospitalizations of adults above the age of 65 (5) (6) (7) (8) . Despite this major health and economic burden, no therapeutics have been licensed specifically for treatment of RSV disease (9).

Anti-RSV drug discovery efforts have increasingly focused on inhibiting the viral RNAdependent RNA polymerase (RdRP) complex (10). The core polymerase machinery comprises 15 the large (L) polymerase protein, its obligatory cofactor, the phosphoprotein (P), and the encapsidated negative-sense RNA genome (10). Allosteric inhibitors of RSV L have demonstrated potent antiviral activity as seen, for instance, with the experimental drug candidate AVG-233 (11) and inhaled PC786 (12) . However, the antiviral indication spectrum of these inhibitors is narrowly focused on RSV. To improve future pandemic preparedness, a broadened 20 activity spectrum reaching beyond the original licensing indication has emerged as an important objective for the development of next generation antivirals. Narrow therapeutic windows of acute viral diseases (13) furthermore require drug administration early after infection, underscoring that next-generation therapeutics against respiratory viruses must be orally bioavailable to meet the time constraints of effective antiviral therapy. 25 In search of suitable candidates meeting these objectives, we examined 4'-FlU. The development of balapiravir, a prodrug of 4'-azidocytidine, against HCV and other flavivirus infections highlights that 4'-substituted ribonucleosides have antiviral promise (14, 15) . Fluorosubstitutions appeared furthermore particularly promising, since the small atomic radius and strong stereo-electronic effect of fluorine can influence the ribose backbone conformation, 30 impacting intra-and intermolecular interactions. Having established broad-spectrum antiviral activity of 4'-FlU in ex vivo models and determined its mechanism of action (MOA), we validated oral efficacy in two different animal models, the RSV mouse model and the SARS-CoV-2 ferret model. This study introduces 4'-FlU as a promising next-generation antiviral candidate with broad-spectrum potential that may provide a therapeutic option against RSV 35 disease and aid in increasing pandemic preparedness.

Having recognized the unmet need of RSV disease as a valid primary indication to advance a novel broad-spectrum antiviral, we assessed activity of 4'-FlU (Fig. 1A) on immortalized HEp-2 40 cells against a recombinant RSV A2-line19F (recRSV A2-L19F) (16) and clinical RSV isolates.

The compound showed potent dose-dependent activity against all RSV strains tested, returning half-maximal efficacious concentrations (EC50 values) ranging from 0.61 to 1.2 µM (Fig. 1B) ( Table S1 ). This cell culture potency was on par with anti-RSV activity of previously reported NHC (17) , the free base of molnupiravir that is currently in clinical development (Fig. S1 ). Global metabolic activity of established human and animal cell lines (HEp-2, MDCK, BHK-T7, BEAS-2B) exposed to up to 500 µM of 4'-FlU remained unaltered (Fig. 1C) (Table S2) . When glucose was replaced with galactose as carbohydrate source to link cell metabolic activity strictly 5 to mitochondrial oxidation (18), we determined a half-maximal cytotoxic concentration (CC50) of 4'-FlU of 250 µM (Fig. 1C) (Table S2) .

When tested on disease-relevant primary human airway epithelial cells (HAE) derived from two different donors (Fig. 1D ), 4'-FlU showed ≥17-fold increased anti-RSV potency but unchanged low cytotoxicity (CC50 169 µM) (Fig. 1E ), resulting in a high selectivity index (SI = EC50/CC50) 10 of ≥1877. Consistent with these findings, in-cell quantitative immunocytochemistry confirmed that 4'-FlU similarly reduced steady-state levels of nuclear-(SDH-A; IC50 272.8 µM) and mitochondrial-(COX-I; IC50 146.8 µM) encoded proteins in HAEs only at high concentrations (Fig. S2) . (Table S1 ).

An initial mechanistic characterization of 4'-FlU in cell-based minireplicon systems revealed inhibition of pneumovirus and paramyxovirus RdRP complex activity (Fig. 1H) (Table S1 ). In accordance with broad-spectrum activity against mononegavirus, the RdRP activity of Nipah virus (NiV), a highly pathogenic zoonotic paramyxovirus with strong pandemic potential (19) , 25 was also efficiently inhibited by 4'-FlU in an NiV minireplicon reporter assay. The antiviral effect of 4'-FlU was dose-dependently reversed by addition of an excess of exogenous pyrimidines, cytidine and uridine, but not purines, to the cultured cells, which furthermore is consistent with competitive inhibition of RdRP activity (2) (Fig. 1I) . 30 

To characterize the molecular MOA of 4'-FlU, we purified recombinant RSV L and P proteins expressed in insect cells ( Fig. 2A) and characterized the performance of the bioactive 5'triphosphate form of 4'-FlU (4'-FlU-TP) in in vitro primer extension assays (20) (Fig. 2B ). In the presence of radio-labelled ATP and an increasing amount of UTP, purified RSV RdRP 35 complexes elongated the primer to the third position, which called for CTP, and continued further upon addition of CTP ( Fig. 2C) (Fig. S3 ) (Data S1). Replacing UTP with 4'-FlU-TP likewise resulted in efficient primer extension up to the third nucleotide, confirming that RSV RdRP recognizes and incorporates 4'-FlU as uridine nucleotide (Fig. 2C ). Incorporation kinetics (21) showed a moderate reduction of substrate affinity for 4'-FlU-TP compared to UTP, reflected 40 by Km values of 24.9 µM versus 6.71 µM (Fig. 2D ). These findings confirmed efficient incorporation of 4'-FlU-TP by RSV RdRP. Further addition of CTP to the reaction mix resulted in limited elongation to gacgcAA(4'-FlU)CA(4'-FlU)A rather than the expected full-length gacgcAA(4'-FlU)CA(4'-FlU)AACA, which suggested delayed chain termination by incorporated 4'-FlU (Fig. 2C ) (Data S1).

When a modified template called for incorporation of only a single UTP (Fig. 2E )(Data S1), we noted accumulation of signal at position i+3 after 4'-FlU-TP, whereas the efficiency of full primer elongation (i+7) was strongly reduced compared to extension after UTP. However, repositioning the incorporation site further downstream in the template triggered polymerase pause at position i (Fig. S4 ), suggesting template sequence dependence of the inhibitory effect. 5 Transcription pauses at i or i+3 were also observed after multiple 4'-FlU incorporations: a UxUxxx template (Fig. 2F ) and direct tandem incorporations (Fig. S4 ) caused termination at position i, whereas increasing spacer length between the uridines to two, three, or four nucleotides resulted in increasingly pronounced pausing at i+3 (Fig. S4 ). This sequencedependent, variable delayed polymerase termination within one to four nucleotides of the 10 incorporation site was equally prominent when we examined de novo initiation of RNA synthesis at the promoter using a synthetic native RSV promoter sequence rather than extension of primertemplate pairs (Fig. S5 ).

Purification of a core SARS-CoV-2 polymerase complex (non-structural proteins (nsp) 7, 8 and 12) from bacterial cell lysates ( 25 

Quantitation of 4'-FlU and its anabolites in primary HAE cells after exposure to 4'-FlU for different times (Fig. 3A ) demonstrated rapid intracellular accumulation of 4'-FlU, reaching a level of 3.42 nmol/million cells in the first hour of exposure (Fig. 3B ). Anabolism to bioactive 4'-FlU-TP was likewise efficient, resulting in concentrations of 10.38 nmol/million cells at peak 30 (4 hours after exposure start) and 1.31 nmol/million cells after 24 hours at plateau. Subsequent wash-out of the compound revealed high metabolic stability of the anabolite, which remained present in sustained concentrations of approximately 1 nmol/million cells over a 6-hour monitoring period, corresponding to an extrapolated half-life of 9.7 hours (Fig. 3C ).

To explore efficacy in a disease-relevant human tissue model, we cultured the HAEs at air-liquid 35 interface, inducing the formation of a well-differentiated 3D epithelium that mimicked hallmarks of a human airway epithelium, including ciliated and mucus-producing cells (22) (Fig. 3D) . When added to the basolateral chamber of the transwells after apical infection of the epithelium with RSV, 4'-FlU potently reduced apically shed progeny virus titers with an EC50 of 55 nM (Fig. 3E) . Overall titer reduction spanned nearly four orders of magnitude, ranging from Confocal microscopy validated formation of a pseudostratified organization of the epithelium with tight junctions in the airway epithelium tissue model (Fig. 3F) , visualized efficient RSV replication in vehicle-treated tissue models (Fig. 3G) , and confirmed near-sterilizing antiviral efficacy in the presence of 50 µM basolateral 4'-FlU (Fig. 3H) (Fig. S7, S8 ). Under these conditions, positive staining for RSV antigen was rarely detected.

To test 4'-FlU efficacy in vivo, we employed the mouse model of RSV infection, challenging 5 animals with recRSV-A2-L19F, which efficiently replicates in mice (16) . In a dose-to-failure study, we infected BALB/cJ mice intranasally and initiated once-daily oral treatment two hours after infection at 0.2, 1, or 5 mg 4'-FlU/kg body weight. Treatment at all dose levels resulted in a statistically significant reduction in lung virus load compared to vehicle-treated animals (Fig.  4A ). The antiviral effect was dose-dependent and approached nearly two orders of magnitude at 10 the 5 mg/kg dose level, the greatest reduction that we have ever observed in this model (17) . Consistent with the observed high metabolic stability in HAEs, a twice-daily dosing regimen did not significantly enhance efficacy (Fig. S9) . Since animal appearance, body weight, temperature (Fig. S10) , and relative lymphocyte and platelet counts (Fig. 4B) (Fig. S11) were unchanged in the 5 mg/kg group compared to vehicle-treated animals, we selected this dose level for the 15 following studies.

For a longitudinal assessment of therapeutic benefit in individual animals, we employed an in vivo imaging system (IVIS) using a red-shifted luciferase-expressing RSV reporter virus (23) that we had generated for this study to maximize signal intensity. Daily imaging (Fig. 4C) (Fig.  S12 ) revealed significant reduction of bioluminescence intensity in lungs of 4'-FlU-treated 20 animals, independent of whether treatment was initiated 24 hours prior to, or 1 hour after, infection (Fig. 4D ). This IVIS profile is consistent with reduced viral replication and ameliorated viral pneumonia in the treated animals.

To probe the therapeutic window of 4'-FlU, we initiated treatment at 2, 12, 24, 36, and 48 hours after infection. All treatment groups showed a statistically significant reduction of lung virus 25 burden compared to vehicle-treated animals, but effect size was dependent on the time of treatment initiation (Fig. 4E) (Fig. S13 ). Based on our experience with therapeutic intervention with related respiratory RNA viruses that cause lethal disease (22), we consider a reduction of lung virus load of at least one order of magnitude required for robust therapeutic benefit. With this request, the therapeutic window of 4'-FlU extended to 24 hours after infection in mice. 

We next tested efficacy against SARS-CoV-2 WA1/2020 in the HAE organoid models grown at air-liquid interface. Independent of the human donor, SARS-CoV-2 replicated efficiently in these disease-relevant tissue models (Fig. 5A-C)(Fig. S14) . Treatment of the infected cultures with basolateral 4'-FlU dose-dependently reduced apical virus shedding, albeit approximately 45-fold 35 less potently (EC50: 2.47 µM) than inhibition of RSV and with a limited maximal effect size of approximately two orders of magnitude at 50 µM (Fig. 5D) . Confocal microscopy revealed that most of the epithelium was negative for staining of the SARS-CoV-2 nucleocapsid protein under these conditions (Fig. 5E) , with only sporadic exceptions of a small number of remaining infected ciliated cells (Fig. 5F)(Fig. S14) .

To assess whether this reduction in viral shedding translates to a significant benefit in vivo, we determined efficacy of oral 4'-FlU against 2019-nCoV/USA-WA1/2020 (WA1/2020, A lineage) and the VoC isolate 2019-nCoV/USA/CA_CDC_5574/2020 (CA/2020, B.1.1.7 lineage) in the ferret model, which recapitulates hallmarks of uncomplicated human infection (3). For informed dose level selection in ferrets, we first determined single oral dose ferret pharmacokinetic (PK) profiles of 4'-FlU. When administered at 15 or 50 mg/kg, peak plasma concentrations (Cmax) of 4'-FlU reached 34.8 and 63.3 µM, respectively, and overall exposure was 154 ± 27.6 and 413.1 ± 78.1 h´nmol/ml, respectively, revealing good oral dose-proportionality (Fig. 6A) (Table S3) . Based on this PK performance, we selected once-daily dosing at 20 mg/kg body weight for 5 efficacy tests (Fig. 6B) .

Intranasal infection of ferrets with 1´10 5 PFU of either WA1/2020 or CA/2020 resulted in rapid viral shedding into the upper respiratory tract. An upper plateau of shed virus was reached in vehicle-treated animals 48 hours after infection at 1.2×10 4 PFU/ml and 2.3×10 2 PFU/ml nasal lavage, respectively (Fig. 6C ). Therapeutic treatment with 4'-FlU initiated 12 hours after infection caused a significant reduction in shed virus burden by approximately three orders of magnitude (WA1/2020) to less than 50 PFU/ml nasal lavage and one order of magnitude (CA/2020), respectively, within 12 hours of treatment onset. Virus loads remained low for the remainder of the study. Viral titers in nasal turbinate tissue extracted four days after infection (Fig. 6D) and associated viral RNA copy numbers ( 

Our anti-RSV efforts have yielded 4'-FlU, an orally efficacious ribonucleoside analog inhibitor with broad-spectrum activity against negative sense RNA viruses of the pneumovirus, rhabdovirus, and paramyxovirus families, which includes the highly pathogenic henipaviruses 25 that carry high pandemic threat potential (19) . In vitro RdRP assays identified polymerase pausing or delayed chain-termination as the primary MOA of 4'-FlU, which is reminiscent of the antiviral effect of remdesivir (24, 25) . In contrast to remdesivir, however, 4'-FlU also induced an immediate RdRP stall after incorporation in a sequence-dependent manner. These properties suggest steric hindrance of the RdRP to advance after incorporation of the compound or to 30 accommodate the next incoming nucleotide as the underlying antiviral mechanism of 4'-FlU.

Albeit with reduced potency, activity of 4'-FlU extended to the positive-sense RNA betacoronavirus SARS-CoV-2. The somewhat lower sensitivity of SARS-CoV-2 to the compound compared to RSV could be due to the exonuclease activity of the coronavirus polymerase complex, which reportedly can eliminate ribonucleoside analogs (26, 27) . However, 35 SARS-CoV-2 polymerase also showed a higher tendency to advance further along the template after 4'-FlU-TP incorporation than RSV RdRP in the in vitro RdRP assays, which do not contain the exonuclease functionality. Accordingly, coronavirus RdRP may also have a somewhat greater capacity to tolerate incorporated 4'-FlU and continue polymerization than mononegavirus polymerase complexes.

Since no small-animal model of RSV infection fully recapitulates all aspects of human RSV disease (28), we employed two complementary infection models to assess antiviral efficacy of 4'-FlU, ex vivo HAE cultures and the in vivo mouse model. Results revealed consistent antiviral efficacy in both systems, indirectly confirming also efficient anabolism in disease-relevant primary human tissues, oral bioavailability of the compound in mice, and accumulation of bioactive 4'-FlU-TP at efficacious levels in mouse lung. Ferret PK profiles validated that 4'-FlU exposure levels are high and dose-proportional after oral administration. Although RSV is known to advance rapidly to viral pneumonia in mice, therapeutic treatment with 4'-FlU demonstrated a 24-hour therapeutic window after infection. Since RSV host invasion is slower in humans (29), these data support that a viable therapeutic window should exist for efficacious 5 treatment of human RSV infection.

When comparing activity of 4'-FlU against SARS-CoV-2 and RSV in cultured cells and welldifferentiated HAEs, anti-SARS-CoV-2 potency was overproportionally lower in the organoid models. RSV tropism in the organoids is restricted to ciliated cells (30, 31) , whereas SARS-CoV-2 can reportedly be found in both ciliated and goblet cells (32) (33) (34) (35) (36) (37) . Conceivably, 4'-FlU anabolism efficiency could be higher in ciliated than in goblet cells, affecting anti-SARS-CoV-2 impact in this system. Importantly, however, once-daily oral treatment of ferrets infected with WA1/2020 or the recently emerged VoC CA/2020 reduced virus burden to an almost undetectable level within 12 hours of treatment initiation. These data confirm broad-spectrum anti-coronavirus efficacy of 4'-FlU in a relevant animal model and suggest that 4'-FlU has 15 greater potential to remain active against future VoCs that may be less responsive to spiketargeting vaccines or antibody therapeutics.

Formal tolerability studies with 4'-FlU are still pending, but the compound was well tolerated by the human organoid models and efficacious in murids and mustelids. Blood analysis of treated mice revealed no global changes in blood cell counts, indicating that treatment had no negative 20 effect on the hematopoietic system. These results establish 4'-FlU as a much-needed novel broad-spectrum antiviral with confirmed efficacy against major RNA virus pathogens, making it a promising therapeutic option for severe RSV disease and an important contributor to further improving pandemic preparedness. 

Figs. S1 to S17

Tables S1 to S3

Data S1 to S2 

Remdesivir for the Treatment of Covid-19 -Final Report

Characterization of orally efficacious influenza drug with high resistance barrier in ferrets and human airway epithelia

Therapeutically administered ribonucleoside analogue MK-4482/EIDD-2801 blocks SARS-CoV-2 transmission in ferrets

The prophylactic and therapeutic activity of a broadly active ribonucleoside analog in a murine model of intranasal venezuelan equine encephalitis 35 virus infection

Respiratory syncytial virus infection in elderly and high-risk adults

Respiratory Syncytial Virus-Associated Hospitalizations Among Young 40 Children

Global Disease Burden Estimates of Respiratory Syncytial Virus-Associated Acute Respiratory Infection in Older Adults in 2015: A Systematic Review and Meta-Analysis

Safety and Anti-viral Effects of Nebulized PC786 in a Respiratory Syncytial Virus Challenge Study

Nebulised ALX-0171 for respiratory syncytial virus lower respiratory tract infection in hospitalised children: a double-blind, randomised, placebocontrolled, phase 2b trial

Activation of peripheral blood mononuclear cells by dengue virus infection depotentiates balapiravir

A randomized, double-blind placebo controlled trial of balapiravir, a polymerase inhibitor, in adult dengue patients

A chimeric A2 strain of respiratory syncytial virus (RSV) with the 20 fusion protein of RSV strain line 19 exhibits enhanced viral load, mucus, and airway dysfunction

Orally Efficacious Broad-Spectrum Ribonucleoside Analog Inhibitor of Influenza and Respiratory Syncytial Viruses

Circumventing the

Crabtree effect: replacing media glucose with galactose increases susceptibility of HepG2 cells to mitochondrial toxicants

The pandemic potential of Nipah virus

The respiratory syncytial virus polymerase can perform RNA synthesis with modified primers and nucleotide analogs

Mechanism of Inhibition of Ebola Virus RNA-Dependent RNA Polymerase by Remdesivir

Quantitative efficacy paradigms of the influenza clinical drug candidate EIDD-2801 in the ferret model

A bright future for bioluminescent imaging in viral 35 research

Mechanism of SARS-CoV-2 polymerase stalling by remdesivir

Template-dependent inhibition of coronavirus RNA-dependent RNA polymerase by remdesivir reveals a second mechanism of action

Coronaviruses lacking exoribonuclease activity are susceptible to lethal mutagenesis: evidence for proofreading and potential therapeutics

Discovery of an RNA virus 3'->5' exoribonuclease that is critically 45 involved in coronavirus RNA synthesis

Single cell resolution of SARS-CoV-2 tropism, antiviral responses, and susceptibility to therapies in primary human airway epithelium

Morphogenesis and cytopathic effect of SARS-CoV-2 infection in human 15 airway epithelial cells

Single-cell longitudinal analysis of SARS-CoV-2 infection in human bronchial epithelial cells. bioRxiv

Goblet Cell Hyperplasia Increases SARS-CoV-2 Infection in COPD. bioRxiv

SARS-CoV-2 receptor ACE2 and TMPRSS2 are primarily expressed in bronchial transient secretory cells

SARS-CoV-2 Reverse Genetics Reveals a Variable Infection Gradient in the Respiratory Tract

Non-linear regression with Michaelis-Menten model. Km and Vmax with 95% confidence intervals (CIs) and goodness of 5 fit (r 2 ) are indicated (n=3). (E,F) Urea-PAGE fractionation of RNA transcripts produced by RSV RdRP in the presence of the indicated templates and nucleotides. 4'-FlU-TP bands were normalized to the corresponding band after UTP incorporation. Bars represent mean and error bar represent standard deviation (n=3). (G) Purified recombinant SARS-CoV-2 RdRP complexes (nsp7, 8, and 12 proteins) used for in vitro RdRP assays as in (A). (H-J) Urea-PAGE 10 fractionation of RNA

We thank C. F. Basler for providing Calu-3 cells, D. Waugh for plasmid pRK792 encoding TEV protease (Addgene plasmid #8830), the Georgia State University High Containment Core and the Department for Animal Research for support, and A. L. Hammond for critical reading of the 30 manuscript.

This work was supported, in part, by Public Health Service grants AI153400 (to RKP), AI071002 (to RKP), and AI141222 (to RKP) from the NIH/NIAID. The funders had no role in